HENGRUI PHARMA (01276.HK): Five Drugs Get Clinical Trial Nod

On 18 November 2026, HENGRUI PHARMA (01276.HK) said it won NMPA approval to run clinical trials for five drug candidates, including two KRAS G12D inhibitors.

NewTimeSpace News: On 18 November 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (stock code: 1276; A-share code: 600276) announced that it and its subsidiaries Suzhou Suncadia Biopharmaceuticals, Shanghai Shengdi Pharmaceutical and Shanghai Hengrui Pharmaceutical have recently received drug clinical trial approval notices issued by the NMPA for HRS-2329 tablets, HRS-6093 tablets, SHR-9839 for injection (sc), HRS-4642 injection and adebrelimab injection, and will commence clinical trials in the near future.

According to the announcement, the applications were accepted on 14 August 2026 and, upon review, the drugs meet the relevant drug registration requirements, with approval granted to conduct clinical trials, specifically an open-label, multicentre Phase IB/II study of HRS-2329 in combination with anti-tumour therapy in patients with solid tumours to assess safety, tolerability and efficacy.

On the candidates, HRS-2329 tablets are an in-house innovative anti-tumour drug for advanced solid tumours harbouring RAS mutations or amplification, with one same-target drug already approved globally; HRS-6093 tablets are a novel oral KRAS G12D inhibitor with no similar product approved in China or overseas; SHR-9839 is a humanised antibody blocking two key signalling pathways, with one same-target drug approved globally for its subcutaneous formulation; HRS-4642 injection is a liposomal KRAS G12D inhibitor with no similar drug approved; and adebrelimab is an anti-PD-L1 antibody, with 2025 global sales of Atezolizumab, Avelumab and Durvalumab totalling about US$11.054 billion.

As at the announcement date, cumulative R&D investment in the five projects was approximately RMB116.2 million, RMB61.8 million, RMB127.8 million, RMB372.3 million and RMB1,370.3 million respectively (all unaudited). The Company cautioned that further clinical trials and NMPA review and approval are required before production and marketing, and that the process is lengthy and subject to uncertainties.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.